Search Technologies

Showing 1-6 of 6 results found

Anti-CD133 Monoclonal Antibodies as Cancer Therapeutics

Researchers at NCI developed a rabbit monoclonal antibody that recognizes the marker for CD133 and is useful in pharmacodynamic testing to inform targeted anti-cancer chemotherapy development and clinical monitoring. CD133 is a cell surface glycoprotein used as a marker and expressed in stem cells such as hematopoietic stem cells, endothelial progenitor cells and neural stem cells. The NCI seeks collaborative co-development or licensing partners for this technology.

Diagnostics
Therapeutics

High-Affinity Rabbit Monoclonal Antibodies for Cancer Treatment

The National Cancer Institute, Laboratory of Molecular Biology seeks parties to co-develop monoclonal antibodies for the treatment of mesothelin-expressing cancers.

Diagnostics
Therapeutics

Co-Transcriptional Assembly of Modified RNA Nanoparticles

The National Cancer Institute seeks parties interested to license a method to generate RNA molecules suitable for nanoparticle and biomedical applications.

Therapeutics
Diagnostics

Removal of Selected Proteins Using Light Energy: Photoimmunotherapy

The National Cancer Institute is seeking parties interested in collaborative research to co-develop or license the in vitro and in vivo removal of targets using light energy.

Therapeutics
Diagnostics
Research Tools

Novel Anti-HIV Compounds Using Peptides or Peptide Mimetics

Novel class of anti-HIV compounds that inhibit viral recognition process and nuclear export activity.

Diagnostics
Therapeutics

Human Antibodies Against Middle East Respiratory Syndrome Coronavirus

The National Cancer Institute is seeking statements of capability or interest from parties interested in collaborative research to co-develop antibody-based therapeutic against MERS-CoV, including animal studies, cGMP manufacturing, and clinical trials.

Diagnostics
Therapeutics

You are here

Product Type

Development Stage

Therapeutic Area

Institutes and Centers